Home » Posts tagged 'DJT Plants Limited'
Tag Archives: DJT Plants Limited
Ananda Developments #ANA – DJT Plants’ Cannabis Flower approved for Israel Import
Ananda, which is creating UK-based operations to grow and provide carbon neutral, consistent, high quality medical cannabis for the UK and international markets, announces that the Government of Israel has granted a licence for cannabis flower grown at Ananda’s subsidiary, DJT Plants Limited (“DJT Plants”) to be imported into Israel. The licence is held by Cannasoul Analytics, the research company which will be analysing DJT Plants’ cannabis flower.
The purpose of obtaining an import licence at this early stage is to ensure that DJT Plants has a clear understanding of all requirements for moving cannabis flower, a controlled drug under the UK Government’s Misuse of Drugs Act 1971, from the UK into Israel. The import licence was awarded by Israel’s Department of Pharmaceutical Import and Narcotics at the Ministry of Health, and by the Ministry of Agriculture and Rural Development Plant Protection and Inspection Services. Appropriate licences will be sought under the relevant UK legislation allowing the export of cannabis flower from the UK nearer to the time of export.
In April 2020, Ananda announced that it would be collaborating with Professor Dedi Meiri, the leading global medical cannabis researcher at The Technion in Israel, to carry out detailed molecular analysis of the strains of cannabis which Ananda proposes to grow and stabilise at DJT Plants.
As part of Ananda’s research plan to stabilise 65 strains of medical cannabis and conduct field trials, future cannabis plant material grown by DJT Plants will be sent to Cannasoul Analytics, an Israel-based commercial research company formed by Professor Dedi Meiri, for analysis of cannabinoid, terpene and flavonoid profiles. It is the view of the Directors of Ananda that Israel continues to be at the forefront of global medical cannabis research and that Israel’s experts have the greatest depth of understanding of the cannabis plant at the molecular level.
Ananda’s ultimate ambition is for DJT Plants to transition to commercial growing of medical cannabis. The Board remains encouraged by progress.
Preparation of documentation continues for the acquisition of the 50% of DJT Group Limited not already owned by Ananda. This work includes the drafting of a range of supporting agreements. Further detail on the proposed acquisition is detailed in the Company’s announcement of 8 June, 2021.
Ananda’s CEO, Melissa Sturgess, commented: “We don’t underestimate the complexity of the work required to grow medical cannabis in the UK. The prize, however, is big; both from a patient care and a financial perspective. Delivering the best quality, consistent medical cannabis medicine to UK and international patients is our clear objective. We continue to work in a focused and diligent manner towards achieving our goals.”
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking YELLOW JERSEY PR |
+44 (0)20 7469 0930
+44 (0) 7585 953 660 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Ananda Developments #ANA – Update on Medical Cannabis Research Growing Facility
Ananda’s ambition is to be a UK-based grower of carbon neutral, consistent, high quality medical cannabis for domestic and international markets. In 2025, the UK medical cannabis market is expected to be worth £450m and the European market is expected to be worth £2.7bn.
HIGHLIGHTS
- Construction works at DJT Plants Limited’s (“DJT Plants”) medical cannabis research growing facility commenced on 4 July 2021
- Dr Hadar Less, DJT Plants’ Chief Grower, has met the UK based construction team on site
- Preparation of documents continues for the acquisition of the 50% of DJT Group Limited (“DJT Group”) not already owned by Ananda
MEDICAL CANNABIS RESEARCH GROWING FACILITY
Since the last update on 25th June 2021, works have commenced on schedule at the UK based research growing facility site. There has been a post-COVID construction boom and although materials costs have risen since the project was originally scoped it is fully funded from Ananda’s current cash reserves. Once construction is complete, DJT Plants will commence planting its first medical cannabis for its research programme. DJT’s ultimate ambition is to transition to commercial growing of medical cannabis. The Board is highly encouraged by progress to date.
Dr Hadar Less, DJT Plants’ Chief Grower, has spent time on site, met with the construction team and scoped out the job description for the Facility Manager who will be recruited to report directly to him.
Dr Less’ expertise is in plant genetics. He was the Agriculture Division Manager at BOL Pharma, CEO of BOL Agrotech and has experience managing large teams. BOL is one of the largest medical cannabis cultivation and production companies in Israel. Israel has a more mature medical cannabis sector than the UK and has, arguably, a medical cannabis prescribing framework that is most like that in the UK in that patients have to have exhausted other forms of medication to be prescribed cannabis. Dr Less was actively involved in the development of DJT Plants’ successful licence application to the Home Office of the UK Government and his experience is directly applicable to DJT’s immediate research initiatives and ultimate commercial growing ambitions.
Ananda’s CEO Melissa Sturgess commented; “Our team grew medical cannabis under contract for GW Pharmaceuticals, providing a great foundation for our ambitions. The first part of our research plan is to stabilise 65 strains of medical cannabis to add to the body of knowledge about growing in UK conditions. We want to create a scientific and operational platform from which we can move to commercial growing.”
Further updates will be provided as plans progress.
ACQUISITION OF 50% OF DJT GROUP NOT ALREADY OWNED BY ANANDA
A circular containing further information and convening a General Meeting to approve, amongst other things, the acquisition by Ananda of the 50% shareholding in DJT Group not currently owned by Ananda, will be sent to Ananda shareholders as soon as possible. A further announcement will be made at that time.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Corporate Broking |
+44 (0)20 7469 0930 |
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Ananda Developments (ANA) – Proposed 100% ownership of DJT Plants Limited
Proposed move to 100% ownership of DJT Plants Limited
The Directors of Ananda announce that non-binding Heads of Terms have been agreed for the proposed acquisition by Ananda of the 50% shareholding in DJT Plants Limited (“DJT Plants”) not currently owned by Ananda (the “Acquisition”).
Ananda intends to become a significant participant in the medicinal cannabis sector as a UK-based grower of consistent, high quality medicinal cannabis for domestic and international markets. The Directors believe that the Acquisition represents a major step towards fulfilling this objective.
HIGHLIGHTS
- On 17 May 2021, DJT Plants was granted a licence to grow >0.2% THC cannabis for research purposes by the UK Government Home Office (the “Licence”)
- DJT Plants is a wholly owned subsidiary of DJT Group Limited (“DJT Group”), which is owned 50/50 by Ananda’s wholly owned subsidiary, Tiamat Agriculture Limited, and Anglia Salads Limited (“Anglia Salads”)
- Consideration for the Acquisition amounts to £7.3 million and will be satisfied by the issue of 790,538,866 ordinary shares of 0.2p each in Ananda (“Ordinary Shares”) to Anglia Salads (the “Vendor”)
- The consideration values each partner’s shareholding in the licence equally. It reflects the Directors’ belief that the Licence represents the majority of Ananda’s current market value and that DJT Plants has the potential to generate significant value and future revenues for the Company
- On completion of the Acquisition, it is proposed that Stuart Piccaver and Simon Goddard, directors of both Anglia Salads and its parent company, JEPCO Limited (“JEPCO”), will join the Board of Ananda as Joint Chief Executive Officer and Chief Financial Officer, respectively
Reason for the Acquisition
The Directors and the Vendor believe that the Acquisition will be mutually beneficial. In particular, they believe that the Acquisition has the potential to deliver the following important advantages:
- captures 100% of the potential commercial growing revenues in Ananda
- ensures that knowhow and developed Intellectual Property is owned by Ananda
- consolidates ownership, management and operation of the Licence and the business in a single entity
- enables working capital requirements to be managed at the DJT Plants’ level
- secures the services of two senior executives with 4 years’ direct experience growing medicinal cannabis in the UK, as well as 30 years of specialist horticultural experience and significant success in horticultural innovation
- secures the growing and agronomic operations services of JEPCO (the 51% owner of Anglia Salads) on a cost-plus basis, meaning Ananda has the ability to execute its strategy on a ‘turn-key’ basis, rather than having to employ, train, manage and retain its own workforce
- gives Ananda immediate access to formal quality systems and procedures which are vital for the cultivation of consistent and high-quality medicinal cannabis
Ananda CEO, Melissa Sturgess, commented:
“Our job now is to stabilise 65 strains of cannabis, conduct research field trials and ready ourselves for the proposed transition to commercial medicinal cannabis growing, subject to further licensing from the Home Office. Stuart has built his agricultural business into the success it is today, as the second largest grower of specialist salad leaves in the UK. He was also responsible for his company’s success growing medicinal cannabis for GW Pharmaceuticals. I look forward to working with him to achieve our objective of being a grower of consistent and high-quality medicinal cannabis for domestic and international markets.”
Incoming Joint-CEO, Stuart Piccaver, commented:
“Following on from the success of obtaining the Home Office licence, it’s now time to turn our vision and plans into reality. I have led 4 significant end to end horticultural developments for blue chip companies in the last 8 years. The basis of these has been to provide solutions to supply chain issues and, as Melissa has commented, one of these was in cannabis. This has given us extensive knowledge on protected growing structures, growing mediums, crop/climate manipulation and the pure practicalities of commercialising various crops. I look forward to joining Melissa and the Ananda team to draw on that experience to ensure our success.”
Background
On 18 May 2021, Ananda announced its 50% owned subsidiary, DJT Plants, had been granted a licence to grow >0.2% THC cannabis for research purposes by the UK Government Home Office. The Licence allows DJT Plants to develop a broad range of cannabis genotypes (“strains”) through a genetic stabilisation and field trials programme, with the goal of growing these genotypes in the UK.
DJT Plants intends to produce a line of 65 stable strains through back crossing six generations from a varied portfolio of 13 seeds that exhibit a range of THC/CBD and other cannabinoid, terpene and flavonoid profiles. The focus will be on strains with metabolic profiles relevant to various health indications which have shown to be receptive to treatment with medical cannabis and for which NICE (the National Institute for Clinical Excellence) has called for further research. They will also be filtered for agronomical traits such as yield and resistance to pathogens, moulds, etc.
The intent is to give DJT Plants a number of its own stable cannabis strains, suitable for growing in UK conditions, with metabolic profiles which have been identified as useful for treating certain medical conditions.
Information on the proposed Directors
On completion of the Acquisition, it is proposed that Stuart Piccaver and Simon Goddard, two highly experienced horticultural, and specifically cannabis cultivation, executives, will join the Board of Ananda.
Stuart Piccaver holds a BSc (Hons) and is a third-generation farmer and CEO of JEPCO and a director of Anglia Salads. With a background and interest in marketing and innovation, he has been the driving force for many of the leading agricultural initiatives and successes of JEPCO and its associated companies.
From a standing start in July 2014, he led the team that proved a concept to grow natural season cannabinoids in the UK, lowering the cost of production by 78%. The project grew 5 hectares under cover to fully assess and master the dynamics of UK production. The project proved its feasibility and created a growing blueprint for a highly scalable production technique.
Simon Goddard is a qualified accountant and has been CFO of JEPCO and Anglia Salads for 19 years. He is responsible for all the strategic, financial and operational aspects of the companies and is also responsible for the Group’s CSR and technical quality standards.
During the initial build-out phase of the Company’s cannabis growing facility, salaries due to Stuart Piccaver and Simon Goddard will be accrued.
Terms of the Acquisition
Pursuant to the proposed terms of the Acquisition, Ananda will acquire the 50 ordinary shares of £1.00 each in DJT Group which it does not currently own, for consideration of £7.3 million, which will be satisfied by the issue of 790,538,866 Ordinary Shares (the “Consideration Shares”), at a deemed price of 0.925p per share (the closing price of Ordinary Shares on 7 June 2021).
The transaction is conditional, amongst other things, on:
- The signing of a legally binding sale and purchase agreement to implement the Acquisition (which will include customary restrictive covenant and non-compete provisions)
- Approval of the Acquisition by Ananda’s shareholders at a general meeting; and
- The receipt of tax advice with respect to certain structural aspects of the transaction
If the Acquisition proceeds to completion on the terms outlined above and no additional Ordinary Shares are issued by the Company in the intervening period, the Vendor will be interested in 790,538,866 Consideration Shares, representing approximately 50% of the Company’s enlarged issued share capital.
Under Rule 9 of the City Code on Takeovers and Mergers (the “Code”), and based on the interest of the Vendor outlined above and on the current issued share capital of Ananda, the allotment of the Consideration Shares will be subject to the Takeover Panel granting the Vendor a waiver of the obligations which would otherwise oblige it to make a general offer to shareholders under Rule 9 of the Code (“Rule 9 Waiver” “Whitewash”); any such Rule 9 Waiver would be subject to the approval of independent shareholders in Ananda at a General Meeting.
There can be no guarantee that such shareholder approval will be obtained or that the Takeover Panel will grant the Rule 9 Waiver required to effect the Acquisition.
DJT Group owns a 100% interest in DJT Plants, which holds the Licence, and 100% of Aristaeus Elements Ltd, a company with certain knowhow about cannabis extraction.
Additional Information
As announced on 18 May 2021, the £300,000 raised by the Company in February 2021 has been allocated to DJT Plants to commence the build out of its research facility at the Licence location. An update on progress will be released in due course.
Ananda continues to hold 2% of the equity in cannabis conference platform and start up adviser iCAN-Israel Limited, and 15% of novel medicinal cannabis vaping technology company Liberty Herbal Technologies Limited. An update on these investments will be released in due course.
General Meeting
A circular containing further information and convening a General Meeting to approve the Acquisition will be sent to Ananda shareholders as soon as possible. A further announcement will be made at that time.
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Investor Relations |
+44 (0)7463 686 497 ir@anandadevelopments.com |
PETERHOUSE CAPITAL LIMITED Corporate Finance Mark Anwyl Allie Feuerlein Corporate Broking |
+44 (0)20 7469 0930 |